Post date May 8, 2023 Experience Kenvue $4.37 billion IPO The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
Post date May 5, 2023 Experience DexCom $1.25 billion convertible notes offering and capped call transactions The 0.375% convertible senior notes are due 2028
Post date May 3, 2023 Experience Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen We are advising Cellular Biomedicine Group on the transaction
Post date April 27, 2023 Experience IDEAYA Biosciences $201 million equity offering The common stock is listed on the Nasdaq Global Select Market
Post date April 21, 2023 Experience Gamida Cell $23 million follow-on offering The shares are listed on the Nasdaq Global Select Market
Post date April 17, 2023 Experience AVITA Medical at-the-market offering The stock is listed on the Nasdaq Global Market
Post date April 14, 2023 Experience InflaRx follow-on offering The shares are listed on the Nasdaq Global Market
Post date March 30, 2023 Experience Medtronic Global Holdings $2 billion notes offering The investment-grade offering comprises two tranches of notes
Post date March 28, 2023 Experience Intercept Pharmaceuticals $100 million at-the-market offering The shares are listed on the Nasdaq Global Select Market
Post date March 22, 2023 Experience Kenvue $7.75 billion senior notes offering The investment-grade offering comprises eight tranches of notes